Please congratulate our incoming leaders, whose terms will officially begin on Dec 1!
Co-Presidents
Jesse Boehm, PhD
Alice Soragni, PhD @alice.soragnilab.com
Secretary
Keith Ligon, MD, PhD
Board Member At-Large
Noah Berlow, PhD
We offer our deep appreciation to the outgoing Board members.
๐ฆ๐๐ฃ๐ ๐ ๐ฒ๐บ๐ฏ๐ฒ๐ฟ๐ โ ๐ฌ๐ผ๐๐ฟ ๐ฉ๐ผ๐ถ๐ฐ๐ฒ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐!
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
โ
Vote now: sfpm.membershiptoolkit.com
๐ฆ๐๐ฃ๐ ๐ ๐ฒ๐บ๐ฏ๐ฒ๐ฟ๐ โ ๐ฌ๐ผ๐๐ฟ ๐ฉ๐ผ๐ถ๐ฐ๐ฒ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐!
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.
โ
Vote now: sfpm.membershiptoolkit.com
๐จExcited to announce the seminar by Kushtrim Kryeziu, PhD (Oslo University) on "Functional Precision Oncology for Metastatic Colorectal Cancer". Join us TODAY, at 12 PM EDT, open to everyone! Don't miss it and consider joining the SFPM
www.sfpm.io/seminars
What incredible news today. I feel so grateful to have worked closely with Tony over the years and to have witnessed firsthand his vision, energy, and commitment to advancing functional precision medicine. I cannot think of a steadier (and more needed) force at the NCI at this time /n
Please join us in thanking him for his service to SfPM and congratulating him on this momentous new chapter. In light of this transition, new Board openings will be announced, with elections to follow. SfPM members will receive additional details in the coming weeks.
His leadership has strengthened our community and accelerated progress toward a future where functional precision medicine improves outcomes for patients everywhere. We are inspired to see Dr. Letai bring his stabilizing, trailblazing force to the NCI at such a critical time for cancer research.
Dr. Letai has helped advance our field with conviction, generosity, and transformative insight. While we are saddened to see him step away from his role at SfPM, we are profoundly grateful for his years of service and unwavering support of our mission.
We want to congratulate our President, Dr. Tony Letai, on his appointment as Director of the NCI. This announcement marks an historic moment for cancer research. Dr. Letai has been a tireless advocate and visionary leader for functional precision medicine ๐งต
www.nih.gov/news-events/...
We were honored to host Jens M. Kelm, PhD (PreComb Therapeutics) for our September seminar.
Dr. Kelm shared insights on:
๐ฏ Dynamic Drug Response Profiling at Scale for Functional Precision Oncology
If you missed the live session, you can now watch it here: www.youtube.com/watch?v=hIkR...
โจ Excited to announce a talk by Jens M. Kelm, PhD (Founder and CSO PreComb Therapeutics AG) on "Dynamic Drug Response Profiling at Scale for Functional Precision Oncology", Join us next Wednesday, September 10, 2025, at 12 PM EDT. Don't miss it!
www.sfpm.io/seminars
Join us this Wednesday 06/11 @ 12:00 PM EST for our monthly SFPM seminar! Dr. Chris Steffi from CompagOs will discuss: "Pioneering Solutions to Understand, Diagnose and Treat Bone Conditions"
More info & link to join: www.sfpm.io/seminars
Precision approaches to tackle acquired resistance to cancer, including model-based functional strategies:
www.nature.com/articles/s41...
In panel discussion on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics. Chair Tony Letai. #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ
Now: Peter Horak. #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ
Now: Keith Ligon. #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ
Two of our Board members, Dr. Letai and Dr. Ligon, are part of this #AACRPM25 panel focused on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics
Join us *today* Wednesday 03/12 @ 12:00 PM EST for our monthly SFPM seminar!
Dr. Perova from EMBL-EBI will discuss: "Leveraging CancerModels.Org: enhancing precision oncology through collaborative cancer model resources"
More info: www.sfpm.io/seminars
Now: Keith Flaherty: Targets and therapeutics in need of functional insights to guide drug development in solid tumors #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ
Continued 2: KF: Genetic evidence points to multiple resistance pathways #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ aacrjournals.org/clincancerres/article/24...
Now: Jeffrey Tyner: Functional omics for novel therapeutic combinations in myeloid malignancies #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ
Continued 2: JT: Experimental approach: primary cells -> overnight exposure -> CITE-seq: dynamic changes and cell persistence under therapeutic selective pressure. With @wondermixtape.bsky.social #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ
Now: Coleman Lindsley: Dyanmic assessment in leukemia. What is minimal residual disease and does it matter? #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ
Now: Sascha Dietrich: Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies #AACRprecmed25 ๐งช๐งฌ๐ฅ๏ธ
On my way to @theaacr.bsky.social special conference in cancer research: functional and genomic precision medicine in cancer. Who else will be there? @alice.soragnilab.com #AACRprecmed25 www.aacr.org/meeting/aacr...
Elaine Mardis giving introductory remarks
Keith Flaherty starting his lecture
This first AACR meeting on functional and genomic precision medicine has officially started! Dr. Mardis gave the introductory remarks followed by our first plenary speaker, Dr. Flaherty, who will focus on the collision of genomic and functional precision medicine #AACRPM25
Do not miss this great talk tomorrow at 5pm CET (12pm EDT): Zinaida Perova (EMBL) "Leveraging CancerModels.Org: Enhancing Precision Oncology Through Collaborative Cancer Model Resources". @thesfpm.bsky.social
www.sfpm.io/seminars
Join us *today* Wednesday 02/12 @ 12:00 PM EST for our monthly SFPM seminar!
Dr. Andrew Satterlee from UNC will discuss overcoming systemic barriers to functional precision medicine using a versatile ex vivo model of patient brain tumors.
More info: www.sfpm.io/seminars
An exciting multicenter phase 2 functional precision medicine clinical trial showing how a rapid ex vivo venetoclax sensitivity assay was the strongest predictor for a favorable treatment response and survival in relapsed/refractory secondary AML
ashpublications.org/blood/articl...
